Reach Us +1-947-333-4405
Virus Safety For Viral Vaccines And Vectors | 67533
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Virus safety for viral vaccines and vectors

16th Euro Global Summit and Expo on Vaccines & Vaccination

Anissa Boumlic-Courtade

Merck Millipore, France

Posters & Accepted Abstracts: J Vaccines Vaccin

DOI: 10.4172/2157-7560-C1-058

Viral vaccines and viral vectors processes present special challenges for virus safety. Viral clearance approaches traditionally used in biopharmaceutical products, such as size exclusion or chemical inactivation, are often not useful when the product itself is a virus or a living cell. Considering lessons learned from the past, regulatory bodies and industry have striven to understand the risk associated with manufacturing of vaccines and novel therapies and to implement barriers to potential viral contaminants. This presentation will examine application of virus safety principles to virus-based products. Selection of virus-free raw materials, safety testing of cell and virus stocks and sensitive tests for detection of contaminating viruses during the manufacturing process are critical elements of a viral safety plan. Viral clearance steps may also be useful in some circumstances, such as the removal of helper viruses from viral vectors. These approaches can be combined to create comprehensive viral safety strategies that minimize the risk of viral contamination.

Email: [email protected]